Literature DB >> 21117169

Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its implication for the control of the metabolism.

Mauro Sola-Penna1, Daniel Da Silva, Wagner S Coelho, Monica M Marinho-Carvalho, Patricia Zancan.   

Abstract

Phosphofructokinase (PFK) is a major regulatory glycolytic enzyme and is considered to be the pacemaker of glycolysis. This enzyme presents a puzzling regulatory mechanism that is modulated by a large variety of metabolites, drugs, and intracellular proteins. To date, the mammalian enzyme structure has not yet been resolved. However, it is known that PFK undergoes an intricate oligomerization process, shifting among monomers, dimers, tetramers, and more complex oligomeric structures. The equilibrium between PFK dimers and tetramers is directly correlated with the enzyme regulation, because the dimer exhibits very low catalytic activity, whereas the tetramer is fully active. Several PFK ligands modulate the enzyme, favoring the formation of its dimers or tetramers. The present review integrates recent findings regarding the regulatory aspects of muscle type PFK and discusses their relation to the control of metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21117169     DOI: 10.1002/iub.393

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  46 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?

Authors:  Sandra Schoors; Anna Rita Cantelmo; Maria Georgiadou; Peter Stapor; Xingwu Wang; Annelies Quaegebeur; Sandra Cauwenberghs; Brian W Wong; Francesco Bifari; Ilaria Decimo; Luc Schoonjans; Katrien De Bock; Mieke Dewerchin; Peter Carmeliet
Journal:  Cell Cycle       Date:  2013-12-13       Impact factor: 4.534

3.  Kinetic and structural investigations into the allosteric and pH effect on the substrate specificity of human epithelial 15-lipoxygenase-2.

Authors:  Netra Joshi; Eric K Hoobler; Steven Perry; Giovanni Diaz; Brian Fox; Theodore R Holman
Journal:  Biochemistry       Date:  2013-10-30       Impact factor: 3.162

4.  Serotonin regulates 6-phosphofructo-1-kinase activity in a PLC-PKC-CaMK II- and Janus kinase-dependent signaling pathway.

Authors:  Wagner Santos Coelho; Mauro Sola-Penna
Journal:  Mol Cell Biochem       Date:  2012-09-26       Impact factor: 3.396

5.  Capillary electrophoresis-based assay of phosphofructokinase-1.

Authors:  Andrew Malina; Sherrisse K Bryant; Simon H Chang; Grover L Waldrop; S Douglass Gilman
Journal:  Anal Biochem       Date:  2014-02-15       Impact factor: 3.365

Review 6.  Cancer metabolism and elevated O-GlcNAc in oncogenic signaling.

Authors:  Zhiyuan Ma; Keith Vosseller
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

7.  Functional lysine modification by an intrinsically reactive primary glycolytic metabolite.

Authors:  Raymond E Moellering; Benjamin F Cravatt
Journal:  Science       Date:  2013-08-02       Impact factor: 47.728

8.  Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.

Authors:  Yun-Yong Park; Sang-Bae Kim; Hee Dong Han; Bo Hwa Sohn; Ji Hoon Kim; Jiyong Liang; Yiling Lu; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Gordon B Mills; Anil K Sood; Ju-Seog Lee
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

Review 9.  Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology.

Authors:  Krithika Vaidyanathan; Sean Durning; Lance Wells
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-14       Impact factor: 8.250

Review 10.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.